New compounds to treat tuberculosis
Development of 1,2,4-Triazolyl Compounds and their derivatives as a New Treatment for Tuberculosis
This study is exploring new medicines made from special compounds to help fight tuberculosis, especially the tough strains that don't respond to current treatments, so that patients can have better options for getting well.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington University NIH-funded |
| Lab location | 1 site (Saint Louis, United States) |
| Project ID | NIH-10998882 on NIH RePORTER |
What this research studies
This research focuses on developing a new class of compounds, specifically nitro-containing 1,2,4-triazoles, to combat tuberculosis (TB), particularly drug-resistant strains. The researchers have identified these compounds as potent inhibitors of Mycobacterium tuberculosis, the bacteria responsible for TB, and are investigating their unique mechanisms of action. By understanding how these compounds work and their effectiveness against resistant strains, the research aims to provide new treatment options for patients with TB. The study includes laboratory experiments to test the compounds' efficacy and safety.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with tuberculosis, particularly those who have strains resistant to standard antibiotic treatments.
Not a fit: Patients with non-tuberculosis infections or those who do not have a diagnosis of tuberculosis may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for tuberculosis, especially for patients with drug-resistant forms of the disease.
How similar studies have performed: Other research has shown promise in developing new antibiotics for tuberculosis, but the specific approach of using nitro-containing 1,2,4-triazoles is relatively novel.
Where this research is happening
Saint Louis, United States
- Washington University — Saint Louis, United States (Active)
Researchers
- Principal investigator: Stallings, Christina Leigh — Washington University
- Study coordinator: Stallings, Christina Leigh
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.